Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
JUBLINGREA
Mr. Deepak Jain · Noida, India
₹738.10
▲+1.62%JUBLINGREA is trading near its 52-week high with strong revenue growth but elevated P/E, reflecting market optimism for its specialty chemicals business.
Exchange
NSI
Currency
INR
Day range
₹727.80 – ₹746.15
52-week range
₹537.30 – ₹845.55
Sector
Basic Materials
Industry
Specialty Chemicals
AI investment rating
AI analysis75% confidence
The stock appears fairly valued at current levels given its premium P/E ratio, though strong growth prospects could justify the valuation over time.
12.7% below the 1-year high · trend up
Hedge-fund memo
Today
Stock gained 1.62% today, trading near the upper end of its daily range.
This week
Continued positive momentum as the stock approaches its 52-week high.
This month
The stock has shown consistent upward movement over the past month, supported by positive analyst sentiment.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
5 headlines · 3 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).
6.68 vs 6.7
-0.30% surprise
5.39 vs 5.1
5.69% surprise
3.5621 vs 3.6
-1.05% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| JUBLINGREA | 116.41B | 37.91 | — | 11.39% | 25.30% |
| LXCHEM | 50.50B | 62.17 | 4.08% | 7.09% | 3.60% |
| CLEAN | 77.49B | 33.75 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Raw material price volatility
Mitigation: Diversified supplier base and strategic inventory management
Regulatory changes in agrochemical sector
Mitigation: Proactive engagement with regulatory bodies and investment in R&D for compliant products
Business intelligence
Competitive moat
Strong R&D capabilities and established distribution network provide a competitive advantage in the specialty chemicals market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Expansion into new specialty chemical segments
Sustained revenue growth guidance
Thesis builder
Bull case
The company's strong revenue growth and market position in specialty chemicals could lead to sustained outperformance.
Base case
Moderate growth with some margin expansion as operational efficiencies improve.
Bear case
Margin pressure from raw material costs and increased competition could limit upside potential.
Time horizon
12-18 months
Est. CAGR
15-20%
Entry (qual.)
Current levels offer a reasonable entry point for long-term investors.
Exit (qual.)
Consider reducing exposure if P/E exceeds 45 or growth decelerates below 15%.
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how JUBLINGREA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain JUBLINGREA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
The stock is attractive for long-term investors despite its premium valuation, given its strong growth trajectory and market position.
simplywall.st·3d ago·published results and forecasts
TradingView·6d ago·maintaining current target
TradingView·6d ago·despite some market movement
TradingView·7d ago·strong growth projections
The Globe and Mail·7d ago·employee stock option grant
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
4.4 vs 4.5
-2.22% surprise
| 15.31% |
| 30.07% |
| -5.50% |
| JUBLPHARMA | 154.81B | 39.02 | 5.96% | 9.72% | 18.70% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹727.80
Resistance (day/52w high)
₹746.15
Volume
2,32,339
Trend
up
RSI (14)
56
MACD
bearish
MA cross
golden
50-day MA
₹677.13
200-day MA
₹666.34
vs 200-DMA
10.8%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.